FDA decisions, funding rounds, and clinical trial readouts that actually matter. One email, every Tuesday, five minutes. Written for the people building and funding the next generation of medicine.
Same structure every week so you always know where to look.
Approvals, CRLs, advisory committee votes. The regulatory decisions that move markets.
Who raised, who acquired, who licensed what. The money behind the molecules.
Phase transitions, data readouts, and the clinical moves that separate winners from also-rans.
XBI performance, big movers, analyst upgrades and downgrades. Just the numbers.
One breakthrough explained in plain language. The kind of thing you'd bookmark but never revisit.
PDUFA dates, conferences, earnings. Know what's coming before everyone else.
Not spectators. The people actually building, funding, and regulating biotech.
R&D leads, CSOs, translational researchers
Biotech analysts, VCs, portfolio managers
RA professionals, policy experts, consultants
CEOs, BD leads, strategy & ops at biotechs
Yes. No paywall, no trials. BiotechWeekly is free and stays free. We make money from relevant sponsors, not subscriptions.
Every Tuesday morning, before the market opens. Built to fit into your coffee routine.
About five minutes. We're ruthless editors. You get signal, not filler.
One click. Every email. No guilt trip.
A team that's spent years in biotech. We read the filings, parse the data, and translate it so you don't have to.
Email sponsor@biotechweekly.com. One sponsor per issue, always relevant. Your message gets full attention.
The biotech news that matters, delivered every Tuesday.
Free forever. Unsubscribe anytime.
One sponsor per issue. High-intent readers. No clutter.